Ohow long has orencia been on the market today?

When did Orencia first hit the market?
Orencia (abatacept) was approved by the U.S. Food & Drug Administration for rheumatoid arthritis in 2005, and later for juvenile idiopathic arthritis in 2008. That approval marked the drug’s entry into commercial sales.
[1]

How long has it been on the market today?
From 2005 to 2026, Orencia has been available for more than 20 years—about 21 years of market presence.
[1]

Who owns the rights and are there still patent protections?
Johnson & Johnson’s biologics division holds the key patents that originally secured market exclusivity. Those patents have now expired, allowing biosimilar competition to enter the U.S. market.
[2]

Can biosimilars compete now, and what does that mean for patients?
With patents expired, approved biosimilars can be prescribed, often at lower costs, expanding access for patients. However, insurance coverage and provider preferences can still influence which product is chosen.
[2]

What’s the current pricing situation?
Because biosimilar competition is in play, average wholesale prices have fallen since the first‑entry period, though brand‑name Orencia remains priced at a premium in many settings.
[2]

---

Sources

1. DrugPatentWatch.com – abatacept market history. https://www.drugpatentwatch.com/patent/abatacept
2. FDA approval and patent status for abatacept (Orencia). https://www.fda.gov/drugs/drug-approvals-and-databases/abatacept-oral-application